

LBT COMPANY PRESENTATION - WHOLESALE INVESTOR CONFERENCE

Digital Asset, AI and Technology Investment Conference, Sydney, Tuesday, 20th August 2024

Adelaide, Australia, 19 August 2024: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in microbiology automation using artificial intelligence, is pleased to announce the Company's CEO and Managing Director, Mr Brent Barnes, will be presenting at the Wholesale Investor Digital Asset, AI and Technology Investment Conference in Sydney (Tuesday, 20th August 2024).

The Company's presentation for the conference is attached.

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

LBT Innovations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com

ASX: LBT COMPANY UPDATE

Proven AI technology disrupting microbiology

Brent Barnes, CEO and Managing Director
August 2024



Disclaimer

This document contains certain forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, we can give no assurance that these expectations will prove to be correct.

Given these uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors, risk and uncertainties including, without limitation, risks associated with estimating potential quantity and timing of sales, risks associated with medical device development and manufacture, risks inherent in the extensive regulatory approval processes mandated by regulatory authorities, delays in clinical trials, future capital needs, general economic uncertainty and other risks detailed from time to time in the Company's announcements to the ASX.

Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.

All reasonable efforts have been made to provide accurate information, but the Company does not undertake any obligation to release publicly any revisions to any "forward-looking statement" to reflect events or circumstances after the date of this presentation, except as may be required under applicable laws. Recipients should make their own enquiries in relation to any investment decisions from a licensed investment advisor.

NOT AN OFFER FOR SECURITIES

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances.

UNITED STATES

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the Company's securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the United States

OTHER JURISDICTIONS

This Presentation may only be accessed in other jurisdictions where it is legal to do so.



**CLEVER CULTURE
SYSTEMS**



LBT INNOVATIONS




Image analysis | machine vision | artificial intelligence


Muffins or chihuahua?



Potato or pit bull?



Machine learning to transform colony detection



Microbiology: a drug manufacturing gatekeeper

Mandatory process in every pharmaceutical manufacturing facility globally

Culture plates



Cleanrooms
(pharmaceutical manufacturing)



5 day incubation



Culture plate reading, reporting. Result to release pharmaceutical product



Critical decision in workflow



No Growth
→ Batch release



Growth detected
→ Batch held
→ Investigation



It matters because mistakes are costly

Quality Control. High cost of failed results

- Up to US\$1bn lost revenue⁵⁻¹
- US\$1m cost per event for failed product⁵⁻¹

Traceability & data integrity. Highly regulated industry

- 116% increase in regulatory observations to drug establishments⁵⁻²
- 86% warning letters cite data integrity issues⁵⁻²

Efficiency. High demand on Microbiologists

- 2 Microbiologists read every environmental monitoring plate
- Inefficient resource use >98% plates have zero growth⁵⁻³



Manual colony counting

- Subjective
- Time Consuming
- Inconsistent colony counts



Digital disruption

Automated reading, interpretation and reporting of microbial growth on culture plates

APAS INDEPENDENCE



Solution: APAS®

Automated Plate Assessment System



Cutting edge AI technology

Machine learning for microbiology applications



Demonstrated performance

Extensive scientific data, faster than microbiologist



Improved data integrity

Automatic data trails and audit reports




Easy integration and user operation

Simple plug and play technology



APAS[®] – the same result every time

Improves traceability, quality and more efficient



AstraZeneca Purchase: 5 instruments / ~\$4m order



Evidence technology is ready for all customers globally

Installation of first 5 expected next 6 months [Aug-24]:

- Multiple global manufacturing locations
- Potential for additional orders to follow
- Majority contract value received as installed

APAS® selected for Environmental Monitoring:

- ~30,000 plates per month at large AZ sites
- >98% of plates are negative
- Occasionally humans make mistakes
- Resolves data integrity challenges



Multiple APAS® Pharma sales commenced in F'25

Deliver + Expand

- AstraZeneca delivery, installation, training of 5 instruments, global sites. Initial rollout expected to be completed in Q3 FY25
- Establish APAS® in routine use: NovaCina
- 2 large multinational customers commencing evaluations
- Create multi-sale opportunities through customer roll-out

